PPCB.O (PPCB.O) News
Follow PPCB.O (PPCB.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Propanc's PRP Increases Chemotherapy Sensitivity in Pancreatic Cancer Cells in Preclinical Study
Propanc Biopharma reported preclinical findings showing PRP pretreatment increased chemotherapy responsiveness in chemotherapy-resistant pancreatic cancer cells. Sequential PRP treatment followed by chemotherapy produced
NEWS | Oct 16, 2026, 12:38 PM UTC
L
Propanc Biopharma reports pilot study shows anti — tumor efficacy for PRP proenzyme formulation in pancreatic, ovarian cancer
Propanc Biopharma reported results already presented in a newly published peer-reviewed pilot study in Scientific Reports on its PRP proenzyme therapy. Preclinical tests showed PRP slowed tumor growth and reduced spread-
NEWS | Oct 14, 2026, 12:35 PM UTC